PD-1和PD-L1在Ⅳ<sub> a</sub>期鼻咽癌组织中的表达及临床意义

doi:10.3760/cma.j.issn.1004-4221.2017.10.005

Abstract
Figure/Table
References()
Related Citation (9)
Read Tracking
Download Tracking

Download: PDF (2453 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS) Supporting Info

Abstract

Objective To measure the expression levels of PD-1 and PD-L1 in the tumor tissues of patients with nasopharyngeal carcinoma (NPC) and to explore the association of their expression with the clinical characteristics and prognosis of NPC patients. Methods The expression levels of PD-1 and PD-L1 in 65 NPC patients were determined by immunohistochemistry, and an analysis was performed on the association of their expression with clinical characteristics and long-term survival in NPC patients. Comparisons between groups were made by the chi-square test or Fisher′s exact test, and the Pearson’s test was used for correlation analysis. Survival rates were calculated using the Kaplan-Meier method, and the log-rank test was used for survival comparison and univariate prognostic analysis. The Cox model was used for multivariate prognostic analysis. Results Expression of PD-1 and PD-L1 was observed in 88%(57/65) and 89%(58/65) of tumor cell surfaces using a cut-off value of 5%, and 38%(25/65) and 58%(38/65) using a cut-off value of 10%. PD-1 expression was significantly correlated with PD-L1 expression using the cut-off value of 5%(P=0.003), and a non-significant correlation was found between the expression levels of PD-1 and PD-L1 using the cut-off value of 10%(P=0.080). There was no significant association between the positive expression rates of PD-1 and PD-L1 and clinicopathological characteristics (P>0.05). The univariate and multivariate survival analyses showed that using the cut-off value of 10%, the patients with positive PD-L1 expression had significantly reduced progression-free survival (hazard ratio[HR]=2.73, 95% confidence interval[CI]:1.07-6.97, P=0.035) and overall survival (HR=3.95, 95%CI:1.09-14.27, P=0.036) compared with those with negative PD-L1 expression. Conclusions PD-1 and PD-L1 are highly expressed in NPC tissues. The expression of PD-L1 is associated with the poor prognosis in patients with stage IVa NPC, and PD-L1 can better predict the poor prognosis using the cut-off value of 10%.

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors

Key words： Programmed death Programmed death ligand Nasopharyngeal neoplasms/radiochemotherapy Prognosis

Received: 08 April 2017

Fund:

Key Laboratory Projects of Xinjiang Uygur Autonomous Region (2015KL021)

Corresponding Authors: Wang Ruozheng,Email:wrz8526@vip.163.com

Cite this article:

. Expression of PD-1 and PD-L1 in patients with stage Ⅳ_{a nasopharyngeal carcinoma and its clinical significance}[J]. Chinese Journal of Radiation Oncology, 2017, 26(10): 1131-1136.

URL:

http://journal12.magtechjournal.com/Jweb_fszlx/EN/10.3760/cma.j.issn.1004-4221.2017.10.005 OR http://journal12.magtechjournal.com/Jweb_fszlx/EN/Y2017/V26/I10/1131

[1] Wang R,Tan Y,Wang X,et al. Prognoses and long-term outcomes of nasopharyngeal carcinoma in han and uyghur patients treated with intensity-modulated radiotherapy in the xinjiang autonomous region of China[J/OL].Plos One,2014,9(11):e111145.DOI:10.1371/journal.pone.0111145.
[2] 区晓敏,史琪,周鑫,等.鼻咽癌IMRT远期疗效和不良反应分析[J].中华放射肿瘤学杂志,2016,25(4):304-309.DOI:10.3760/cma.j.issn.1004-4221.2016.04.002.
Ou XM,Shi Q,Zhou X,et al. Analysis of long term efficacy and adverse reactions of nasopharyngeal carcinoma IMRT[J].Chin J Radiat Oncol,2016,25(4):304-309.DOI:10.3760/cma.j.issn.1004-4221.2016.04.002.
[3] 易俊林,高黎,黄晓东等.416例鼻咽癌调强放疗远期生存与影响因素分析[J].中华放射肿瘤学杂志,2012,21(3):196-200.DOI:10.3760/cma.j.issn.1004-4221.2012.03.002.
Yi JL,Gao L,Huang XD,et al. Long term survival and influencing factors of intensity-modulated radiotherapy for nasopharyngeal carcinoma:a report of 416 cases[J].Chin J Radiat Oncol,2012,21(3):196-200.DOI:10.3760/cma.j.issn.1004-4221.2012.03.002.
[4] Lee AW,Ma BB,Ng WT,et al. Management of Nasopharyngeal Carcinoma:Current Practice and Future Perspective[J].J Clin Oncol.2015,33(29):3356-64.DOI:10.1200/JCO.2015.60.9347.
[5] Jin Y,Shi YX,Cai XY,et al. Comparison of five cisplatin-based regimens frequently used as the first-line protocols in metastatic nasopharyngeal carcinoma[J].J Cancer Res Clin Oncol,2012,138(10):1717-25.DOI:10.1007/s00432-012-1219-x.
[6] Hawkes EA,Grigg A,Chong G.Programmed cell death-1 inhibition in lymphoma[J].Lancet Oncol,2015,16(5):e234-e245.DOI:10.1016/S1470-2045(15)70103-8.
[7] 王倩蓉,李宝生.PD-1/PD-L1单抗联合放疗治疗实体瘤研究进展[J].中华放射肿瘤学杂志,2016,25(12):1375-1378.DOI:10.3760/cma.j.issn.1004?4221.2016.12.022.
Wang QR,Li BS.Research progress of PD-1/PD-L1 monoclonal antibody combined with radiotherapy for solid tumors[J].Chin J Radiat Oncol,2016,25(12):1375-1378.DOI:10.3760/cma.j.issn.1004?4221.2016.12.022.
[8] Kwon ED,Drake CG,Scher HI,et al. Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043):a multicentre,randomised,double-blind,phase 3 trial[J].Lancet Oncol,2014,15(7):700-712.DOI:10.1016/S1470-2045(14)70189-5.
[9] Ohaegbulam KC,Assal A,Lazar-Molnar E,et al. Human cancer immunotherapy with antibodies to the PD-1 and PD-L1 pathway[J].Trends Mol Med,2015,21(1):24-33.DOI:10.1016/j.molmed.2014.10.009.
[10] Swaika A,Hammond WA,Joseph RW.Current state of anti-PD-L1 and anti-PD-1 agents in cancer therapy[J].Mol Immunol,2015,67(2):4-17.DOI:10.1016/j.molimm.2015.02.009.
[11] Chow L Q,Haddad R,Gupta S,et al. Antitumor activity of pembrolizumab in biomarker-unselected patients with recurrent and/or metastatic head and neck squamous cell carcinoma.Results From the Phase Ib KEYNOTE-012 Expansion Cohort[J].J Clin Oncol,2016,34(32):3838-3845.DOI:10.1200/JCO.2016.68.1478.
[12] Fang W,Zhang J,Hong S,et al. EBV-driven LMP1 and IFN-γ up-regulate PD-L1 in nasopharyngeal carcinoma:Implications for oncotargeted therapy[J].Oncotarget,2014,5(23):12189-202.DOI:10.18632/oncotarget.2608.
[13] Zhang J,Fang W,Qin T,et al. Co-expression of PD-1 and PD-L1 predicts poor outcome in nasopharyngeal carcinoma[J].Med Oncol.,2015,32(3):1-6.DOI:10.1007/s12032-015-0501-6.
[14] Lee VHF,Lo AWI,Leung CY,et al. Correlation of PD-L1 expression of tumor cells with survival outcomes after radical intensity-modulated radiation therapy for non-metastatic sasopharyngeal carcinoma[J/OL].Plos One,2016,11(6):e0157969.DOI:10.1371/journal.pone.0157969.
[15] Kleffel S,Posch C,Barthel S,et al. Melanoma Cell-Intrinsic PD-1 Receptor Functions Promote Tumor Growth[J].Cell,2015,162(6):1242. DOI:10.1016/j.cell.2015.08.052.
[16] Zhou Y,Miao J,Wu H,et al. PD-1 and PD-L1 expression in 132 recurrent nasopharyngeal carcinoma:the correlation with anemia and outcomes[J].Oncotarget,2017.DOI:10.18632/oncotarget.17214.
[17] Chan OS,Kowanetz M,Ng WT,et al. Characterization of PD-L1 expression and immune cell infiltration in nasopharyngeal cancer.[J].Oral Oncol,2017,67:52-60. DOI:10.1016/j.oraloncology.2017.02.002.
[18] Zhang Y,Kang S,Shen J,et al. Prognostic significance of programmed cell death 1(PD-1) or PD-1 ligand 1(PD-L1) Expression in epithelial-originated cancer:a meta-analysis[J].Medicine,2015,94(6):e515. DOI:10.1097/MD.0000000000000515.
[19] Zhou Y,Shi D,Miao J,et al. PD-L1 predicts poor prognosis for nasopharyngeal carcinoma irrespective of PD-1 and EBV-DNA load[J].Sci Rep,2017,7:43627. DOI:10.1038/srep43627.